Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inozyme Pharma, Inc. (INZY) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights – Interim data readouts from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency expected in September 2023 – – Plasma pyrophosphate to serve as primary endpoint in the U.S. and co-primary endpoint in the EU for ENERGY-3 pediatric pivotal trial for ENPP1 Deficiency; initiation expected in October 2023 – – Cash, cash equivalents, and short-term investments as of June 30, 2023, together with proceeds from July 2023 offering, expected to fund cash flow requirements into the fourth quarter of 2025 –"
05/09/2023 8-K Quarterly results
Docs: "Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights - Upcoming clinical and regulatory milestones remain on track with previous guidance – - Current cash, cash equivalents and short-term investments anticipated to fund cash flow requirements into the fourth quarter of 2024 - BOSTON, May 9, 2023 – Inozyme Pharma, Inc. , a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the first quarter ended March 31, 2023, and provided business highlights. “We are continuing to advance INZ-701 and look forward to initiating a pivotal trial for pediatric patients with ENPP1 Deficiency in the third quarter of this y..."
03/22/2023 8-K Quarterly results
11/10/2022 8-K Quarterly results
08/15/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
03/15/2022 8-K Quarterly results
08/11/2021 8-K Quarterly results
Docs: "Inozyme Pharma Reports Q2 2021 Financial Results and Provides Business Highlights - Received Orphan Drug Designation from the European Medicines Agency for INZ-701 for the treatment of ABCC6 Deficiency –"
05/12/2021 8-K Quarterly results
03/25/2021 8-K Quarterly results
11/12/2020 8-K Quarterly results
Docs: "Inozyme Pharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights"
09/03/2020 8-K Quarterly results
Docs: "Inozyme Pharma Reports Second Quarter 2020 Financial Results and Provides Business Highlights"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy